Gene News and Research

Latest Gene News and Research

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

7 Nov 2012

Researchers succeed in teaching computers how to identify commonalities in DNA sequences

Johns Hopkins researchers have succeeded in teaching computers how to identify commonalities in DNA sequences known to regulate gene activity, and to then use those commonalities to predict other regulatory regions throughout the genome. The tool is expected to help scientists better understand disease risk and cell development.

7 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

Gene silencing technology used to fight RSV and influenza

New hope has arrived for the fight against two deadly viral infections, RSV and influenza, as Griffith researchers prepare to develop a cutting-edge approach to treatment delivery.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Study: Superbug MRSA prevalent at wastewater treatment plants in the U.S.

A team led by researchers at the University of Maryland School of Public Health has found that the "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is prevalent at several U.S. wastewater treatment plants (WWTPs).

6 Nov 2012

Dysregulation of CISTR-ACT causes brachydactyly type E

The patients have single short fingers (metacarpals) and toes (metatarsals) and can be restricted in growth due to a shortened skeleton. This hereditary disease is called brachydactyly type E (Greek for short fingers).

6 Nov 2012

Affymetrix reports net loss of $17.9 million for third quarter 2012

Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.

5 Nov 2012

Genetic polymorphisms linked with community-acquired pneumonia

Seven genetic polymorphisms have been shown to be associated with community-acquired pneumonia, research shows.

5 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Weill Cornell researchers awarded Grand Challenges Explorations grants

Weill Cornell Medical College announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

3 Nov 2012

New tool can particularly sort tumor-causing cancer cells

A new tool developed by scientists at The Methodist Hospital separates tumor-causing cancer cells from more benign cells by subjecting the cells to a microscopic game of Plinko -- except only the squishiest cells make it through.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

Mass spectrometry can help visualize how drugs work inside living cells to kill infectious microbes

Weill Cornell Medical College researchers report that mass spectrometry, a tool currently used to detect and measure proteins and lipids, can also now allow biologists to "see" for the first time exactly how drugs work inside living cells to kill infectious microbes.

3 Nov 2012

Studies show standardizing computer programs help improve genetic testing for Lynch Syndrome

Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."

3 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

Gene News and Research

Latest Gene News and Research

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

Researchers succeed in teaching computers how to identify commonalities in DNA sequences

Biologists determine how blind mole rats fight off cancer

Gene silencing technology used to fight RSV and influenza

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Alnylam third quarter 2012 revenues decrease to $16.8 million

Study: Superbug MRSA prevalent at wastewater treatment plants in the U.S.

Dysregulation of CISTR-ACT causes brachydactyly type E

Affymetrix reports net loss of $17.9 million for third quarter 2012

Genetic polymorphisms linked with community-acquired pneumonia

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Weill Cornell researchers awarded Grand Challenges Explorations grants

New tool can particularly sort tumor-causing cancer cells

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

Mass spectrometry can help visualize how drugs work inside living cells to kill infectious microbes

Studies show standardizing computer programs help improve genetic testing for Lynch Syndrome

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

eBook: Using iPSCs models for human disease research and drug discovery eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics